ThrombosisChip
Thrombophilia, a pathological tendency to develop thrombosis, is a complex condition involving genetic and environmental factors, as well as gene-environment interactions. According to the GAIT study 1, genetic factors explain 60% of the aetiology of thrombosis.
One-third of patients with congenital thrombophilia have their first episode of Deep Vein Thrombosis (DVT) at the same time that an acquired risk factor, such as pregnancy, is seen. Identifying pregnant women at high risk could decrease the incidence and complications of this disease during pregnancy.
Which patients is it most useful for?
- Family history of thrombophilia.
- High-risk pregnancies (pre-eclampsia, implantation failures,
recurrent miscarriages...).
- 265€
- Sample:
Blood EDTA or Saliva - Volume:
4 ml - Storage of sample:
20+/-5 oC - Turnaround time: 30 working days (May vary)
Benefits
Genetic panel
It includes 12 genetic variants in 7 of the most relevant risk genes (ABO gene, F2, F5, F12, F13, serpin A10 and serpin C1).
Risk score
Unique algorithm that weights the risk of each factor using genetic and clinical data.
Recommendations report
Personalised recommendations report from Dr. José Manuel Soria.
What information does it provide?
ThrombosisChip detects expected thrombophilia with a blood test by studying 12 allelic variants in 7 genes related to risk of Venous Thromboembolic Disease (VTE) in the coagulation cascade.
